和黃醫藥(00013.HK)與恒瑞醫藥達成合作並啟動索凡替尼(surufatinib)聯合卡瑞利珠單抗(camrelizumab)用於治療初治胰腺導管腺癌的II/III期研究
格隆匯5月14日丨和黃醫藥(00013.HK)發佈公吿,今日宣佈啟動一項中國II/III 期臨牀試驗,以評估和黃醫藥的候選藥物索凡替尼(surufatinib)、江蘇恒瑞醫藥股份有限公司(“恒瑞醫藥”)的PD-1 抗體卡瑞利珠單抗(camrelizumab)、白蛋白結合型紫杉醇(nab-paclitaxel)和吉西他濱(gemcitabine)的聯合療法用於一線治療轉移性胰腺導管腺癌(PDAC)患者。胰腺導管腺癌是一種外分泌腫瘤,也是最常見的胰腺癌形式。首名受試者已於2024年5月8日接受首次給藥治療。
和黃醫藥首席執行官兼首席科學官蘇慰國博士表示:“包括來自ASCO胃腸癌研討會上發表的一項研究者發起的臨牀試驗在內的新數據表明,與現有基於化療的轉移性胰腺導管腺癌治療相比,索凡替尼、卡瑞利珠單抗和化療的聯合療法具有良好的療效。 我們希望這項合作將為患者帶來有望改變生活的創新治療選擇。 ”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.